<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448421</url>
  </required_header>
  <id_info>
    <org_study_id>DEFLECT I</org_study_id>
    <nct_id>NCT01448421</nct_id>
  </id_info>
  <brief_title>DEFLECT I: Keystone Heart Embolic Deflection Trial</brief_title>
  <official_title>A Prospective, Single Arm Feasibility Study to Evaluate the Safety and Performance of the Keystone Heart Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keystone Heart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keystone Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study using the Keystone Heart Embolic Deflection Device and involving&#xD;
      patients with aortic stenosis (a disease of the aortic valve), to be treated with&#xD;
      Transcatheter Aortic Valve Replacement (TAVR).&#xD;
&#xD;
      The TAVR procedure consists in replacing the diseased aortic valve by a new artificial valve.&#xD;
      The new valve is put into place using a long, thin tube called a catheter that is inserted&#xD;
      into a small incision (cut) in the patient's groin and threaded through his/her arteries up&#xD;
      to the heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a research study using the Keystone Heart Embolic Deflection Device and involving&#xD;
      patients with aortic stenosis (a disease of the aortic valve), to be treated with&#xD;
      Transcatheter Aortic Valve Replacement (TAVR).&#xD;
&#xD;
      The TAVR procedure consists in replacing the diseased aortic valve by a new artificial valve.&#xD;
      The new valve is put into place using a long, thin tube called a catheter that is inserted&#xD;
      into a small incision (cut) in the patient's groin and threaded through his/her arteries up&#xD;
      to the heart.&#xD;
&#xD;
      During the TAVR procedure, there is a risk that an abnormal particle (called embolism) could&#xD;
      break off from inside the arteries and travel to the brain. The embolism could be made of&#xD;
      clumps of blood (clots), air, part of your body tissue, or part of a medical device. If the&#xD;
      embolism is carried through the blood to the brain, it could cause a stroke or other&#xD;
      neurological (brain) problems. A stroke happens when blood flow to a part of the brain is&#xD;
      blocked, causing brain cells to die.&#xD;
&#xD;
      The Keystone Heart Embolic Deflection Device has been developed to prevent an embolism from&#xD;
      going to the brain and causing a stroke or other brain damage. The device is a wire mesh&#xD;
      filter that covers the vessels that carry blood to brain, deflecting any any blood clots or&#xD;
      other materials away from the patient's brain and towards the lower body, where they are less&#xD;
      likely to cause harm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance)</measure>
    <time_frame>During the procedure</time_frame>
    <description>Device ability to access and deploy in the aortic arch and position the device to cover all three vessels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events Related to Investigational Device and Procedure</measure>
    <time_frame>30 days follow-up</time_frame>
    <description>Incidence of investigational device- and investigational procedure-related serious adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Keystone Heart Embolic Deflection Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protected Transcatheter Aortic Valve Replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Keystone Heart Embolic Deflection Device</intervention_name>
    <description>The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.</description>
    <arm_group_label>Keystone Heart Embolic Deflection Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥18 years of age.&#xD;
&#xD;
          2. Patient meets indications for TAVR procedure.&#xD;
&#xD;
          3. The patient is willing to comply with protocol-specified follow-up evaluations.&#xD;
&#xD;
          4. The patient, or legally authorized representative, has been informed of the nature of&#xD;
             the study, agrees to its provisions and has provided written informed consent,&#xD;
             approved by the appropriate Medical Ethics Committee or Institutional Review Board.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing TAVR via the trans-axillary, subclavian, or direct aortic route&#xD;
&#xD;
          2. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to index procedure per site standard&#xD;
             test.&#xD;
&#xD;
          3. Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours&#xD;
             preceding the index procedure (according to definition) or AMI &gt;72 hours preceding the&#xD;
             index procedure, in whom creatine kinase and creatine kinase have not returned to&#xD;
             within normal limits at the time of procedure.&#xD;
&#xD;
          4. Patients who are currently experiencing clinical symptoms consistent with new onset&#xD;
             AMI, such as nitrate-unresponsive prolonged chest pain.&#xD;
&#xD;
          5. Patients with impaired renal function (estimated Glomerular Filtration Rate [estimated&#xD;
             Glomerular Filtration Rate] &lt;30, calculated from serum creatinine by the&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          6. Patients with a platelet count of &lt;100.000 cells/mm³ or &gt; 700.000 cells/mm³ or a white&#xD;
             blood cell &lt; 3000 cells/mm³ within 7 days prior to index procedure.&#xD;
&#xD;
          7. Patients with a history of bleeding diathesis or coagulopathy or patients in whom&#xD;
             anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse&#xD;
             transfusion.&#xD;
&#xD;
          8. Patients who have received any organ transplant or are on a waiting list for any organ&#xD;
             transplant.&#xD;
&#xD;
          9. Patients with known other medical illness or known history of substance abuse that may&#xD;
             cause non-compliance with the protocol, confound the data interpretation or is&#xD;
             associated with a life expectancy of less than one year.&#xD;
&#xD;
         10. Patients with known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or&#xD;
             contrast sensitivity that cannot be adequately pre-medicated.&#xD;
&#xD;
         11. Patients with a history of a stroke or transient ischemic attack (TIA) within the&#xD;
             prior 6 months.&#xD;
&#xD;
         12. Patients with an active peptic ulcer or history of upper gastrointestinal (GI)&#xD;
             bleeding within the prior 6 months.&#xD;
&#xD;
         13. Patients presenting with cardiogenic shock.&#xD;
&#xD;
         14. Patients with severe peripheral arterial disease that precludes 9 French sheath&#xD;
             vascular access.&#xD;
&#xD;
         15. Patients with documented friable or mobile atherosclerotic plaque in the aortic arch.&#xD;
&#xD;
         16. Patients with contraindication to cerebral MRI.&#xD;
&#xD;
         17. Patients who have a planned treatment with any other investigational device or&#xD;
             procedure during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mullen, Md.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Heart Hospital, London, UK</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Keystone Heart Embolic Deflection Device</title>
          <description>Protected Transcatheter Aortic Valve Replacement&#xD;
Keystone Heart Embolic Deflection Device: The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>all baseline characteristics were provided for study participants</population>
      <group_list>
        <group group_id="B1">
          <title>Keystone Heart Embolic Deflection Device</title>
          <description>Protected Transcatheter Aortic Valve Replacement&#xD;
Keystone Heart Embolic Deflection Device: The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance)</title>
        <description>Device ability to access and deploy in the aortic arch and position the device to cover all three vessels.</description>
        <time_frame>During the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Keystone Heart Embolic Deflection Device</title>
            <description>Protected Transcatheter Aortic Valve Replacement&#xD;
Keystone Heart Embolic Deflection Device: The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance)</title>
          <description>Device ability to access and deploy in the aortic arch and position the device to cover all three vessels.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Serious Adverse Events Related to Investigational Device and Procedure</title>
        <description>Incidence of investigational device- and investigational procedure-related serious adverse events</description>
        <time_frame>30 days follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Keystone Heart Embolic Deflection Device</title>
            <description>Protected Transcatheter Aortic Valve Replacement&#xD;
Keystone Heart Embolic Deflection Device: The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events Related to Investigational Device and Procedure</title>
          <description>Incidence of investigational device- and investigational procedure-related serious adverse events</description>
          <units>serious adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Keystone Heart Embolic Deflection Device</title>
          <description>Protected Transcatheter Aortic Valve Replacement&#xD;
The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Upon completion of the Clinical Trial the Principal Investigator and Sponsor shall co-operate in producing a report of the Clinical Trial. The Sponsor will provide the Institution and/or Principal Investigator with the necessary results, and the Institution and/or Principal Investigator will be authorized to publish the results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Jaffe, VP RA./QA/CA</name_or_title>
      <organization>keystoneheart</organization>
      <phone>97246158005 ext 8005</phone>
      <email>karen.jaffe@keystoneheart.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

